China Biotech Services Holdings Limited provided consolidated earnings guidance for the year ended December 31, 2022. For the year, the company expected to record a net profit attributable to the owners of the Company of not less than HKD 200,000,000 for FY2022 as compared with that of approximately HKD 19,385,000 for the year ended 31 December 2021, representing a significant increase in profit attributable to the owners of the Company of not less than approximately 9.32 times.